NEW YORK (GenomeWeb News) – CombiMatrix has signed an agreement with an institutional investor for a registered direct offering that is expected to provide the firm with $2 million in gross proceeds, or $1.76 million in net proceeds.

The firm said that it has entered into a definitive purchase agreement with the unnamed investor to purchase 130,000 shares of common stock for $3.05 per share and approximately 1,610 units consisting of Series B convertible preferred stock and warrants. Shares of CombiMatrix closed Tuesday at $3.20 on the Nasdaq.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.